Page 259 - Haematologica March 2020

Outcomes of Richter transformation
leukemia. Cancer. 2003;97(7):1711-1720.
15. Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I-II study of oxaliplatin, fludara- bine, cytarabine, and rituximab combina- tion therapy in patients with Richter's syn- drome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol.
2008;26(2):196-203.
16. Tsimberidou AM, Wierda WG, Wen S, et
al. Phase I-II clinical trial of oxaliplatin, flu- darabine, cytarabine, and rituximab thera- py in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syn- drome. Clin Lymphoma Myeloma Leuk. 2013;13(5):568-574.
17. Durot E, Michallet A-S, Leprêtre S, Le Q-H, Leblond V, Delmer A. Platinum and high- dose cytarabine-based regimens are effi- cient in ultra high/high-risk chronic lym- phocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study. European Journal of Haematology. 2015;95(2):160-167.
18. Rogers KA, Huang Y, Ruppert AS, et al. A single-institution retrospective cohort study of first-line R-EPOCH chemoim- munotherapy for Richter syndrome demonstrating complex chronic lympho- cytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol. 2018;180(2):259-266.
19. Tsimberidou AM, O'Brien S, Khouri I, et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunother- apy with or without stem-cell transplanta- tion. J Clin Oncol. 2006;24(15):2343-2351.
20. Cwynarski K, van Biezen A, de Wreede L, et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syn- drome): a retrospective analysis from the chronic lymphocytic leukemia subcommit- tee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012; 30(18):2211-2217.
21. Kharfan-Dabaja MA, Kumar A, Stingo FE, et al. Allogeneic hematopoietic cell trans- plantation for Richter syndrome: a single- center experience. Clin Lymphoma Myeloma Leuk. 2018;18(1):e35-e39.
22. Bounaix L, Nguyen S, Blaise D, et al. Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Richter's Syndrome:the SFGM-TC Experience. Blood. 2018;132(Suppl 1):3457.
23. El-Asmar J, Kharfan-Dabaja MA. Hematopoietic cell transplantation for Richter syndrome. Biol Blood Marrow Transplant. 2016;22(11):1938-1944.
24. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lym- phoma identified by gene expression profil- ing. Nature. 2000;403(6769):503-511.
25. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(25):1937-1947.
26. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classifica- tion of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
27. Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of dif- fuse large B-cell lymphoma using gene expression in formalin-fixed paraffin- embedded tissue. Blood. 2014;123(8):1214- 1217.
28. Riedell PA, Smith SM. Double hit and dou- ble expressors in lymphoma: Definition and treatment. Cancer. 2018;124(24):4622- 4632.
29. Friedberg JW. How I treat double-hit lym- phoma. Blood. 2017;130(5):590-596.
30. Shanafelt TD, Jenkins G, Call TG, et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer. 2009;115(2):363-372.
31. Nabhan C, Chaffee KG, Slager SL, et al. Analysis of racial variations in disease char- acteristics, treatment patterns, and out- comes of patients with chronic lymphocyt- ic leukemia. Am J Hematol. 2016;91(7):677- 680.
32. Eyre TA, Clifford R, Bloor A, et al. NCRI phase II study of CHOP in combination with ofatumumab in induction and mainte- nance in newly diagnosed Richter syn- drome. Br J Haematol. 2016;175(1):43-54.
33. Fidai S, Sukhanova M, Chiu BC-H, et al. <em>TP53</em> Aberrations By FISH in CLL and Complex Karyotype at Transformation Predict for Worse Outcome in Diffuse Large B-Cell Lymphoma - Richter Transformation: A Single Institution Series of 75 DLBCL-RT Cases. Blood. 2018;132(Suppl 1):2984.
34. Fan L, Wang L, Zhang R, et al. Richter trans- formation in 16 of 149 Chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(9):1749-1756.
35. Fabbri G, Khiabanian H, Holmes AB, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med. 2013; 210(11):2273-2288.
36. Abrisqueta P, Delgado J, Alcoceba M, et al. Clinical outcome and prognostic factors of patients with Richter's syndrome: retro- spective multicenter study of the Spanish Chronic Lymphocytic Leukemia (CLL) Study Group (GELLC). Blood. 2017; 130(Suppl 1):2995.
37. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of Ibrutinib therapy discontinu- ation and outcomes in patients with chron- ic lymphocytic leukemia. JAMA Oncol. 2015;1(1):80-87.
38. Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lym- phocytic leukemia after discontinuing ibru- tinib. Blood. 2015;125(13):2062-2067.
39. Davids MS, Huang Y, Rogers KA, et al. Richter's syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy. J Clin Oncol. 2017; 35(15_suppl):7505.
40. Anderson MA, Tam C, Lew TE, et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood. 2017; 129(25):3362-3370.
41. Tsang M, Shanafelt TD, Call TG, et al. The efficacy of ibrutinib in the treatment of Richter syndrome. Blood. 2015; 125(10):1676-1678.
42. Hillmen P, Schuh A, Eyre TA, et al. Acalabrutinib monotherapy in patients with Richter transformation from the Phase 1/2 ACE-CL-001 clinical study. Blood. 2016;128(22):60.
43. Ding W, LaPlant BR, Call TG, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017;129(26):3419-3427.
44. Davids MS, Roberts AW, Seymour JF, et al. Phase I First-in-human Study of Venetoclax in patients with relapsed or refractory non- Hodgkin Lymphoma. J Clin Oncol. 2017; 35(8):826-833.
45. Jain N, Ferrajoli A, Basu S, et al. A Phase II Trial of Nivolumab combined with Ibrutinib for patients with Richter transfor- mation. Blood. 2018;132(Suppl 1):296.
46. Mato AR, Svoboda J, Luning Prak ET, et al. Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG- 1101) and Pembrolizumab in patients with relapsed/refractory CLL and Richter's trans- formation. Blood. 2018;132(Suppl 1):297.
47. Younes A, Brody J, Carpio C, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lym- phocytic leukaemia: a phase 1/2a study. Lancet Haematol. 2019;6(2):e67-e78.
48. Turtle CJ, Hay KA, Hanafi LA, et al. durable molecular Remissions in chronic lympho- cytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells afterfailure of Ibrutinib. J Clin Oncol. 2017; 35(26):3010-3020.
49. Barrio S, Shanafelt TD, Ojha J, et al. Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome. Leukemia. 2017;31(1):170-176.
50. Popp HD, Flach J, Brendel S, et al. Accumulation of DNA damage and alter- ation of the DNA damage response in mon- oclonal B-cell lymphocytosis and chronic lymphocytic leukemia. Leuk Lymphoma. 2018;1-10.
haematologica | 2020; 105(3)
773